» Articles » PMID: 33618513

Economic Burden of Recurrent Clostridioides Difficile Infection in Adults Admitted to Spanish Hospitals. A Multicentre Retrospective Observational Study

Overview
Specialty Pharmacology
Date 2021 Feb 23
PMID 33618513
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Clostridioides difficile infection (CDI) is associated with increased hospital stays and mortality and a high likelihood of rehospitalization, leading to increased health resource use and costs. The objective was to estimate the economic burden of recurrent CDI (rCDI).

Methods: Observational, retrospective study carried out in six hospitals. Adults aged ≥18 years with ≥1 confirmed diagnosis (primary or secondary) of rCDI between January 2010 and May 2018 were included. rCDI-related resource use included days of hospital stay (emergency room, ward, isolation and ICU), tests and treatments. For patients with primary diagnosis of rCDI, the complete hospital stay was attributed to rCDI. When diagnosis of rCDI was secondary, hospital stay attributed to rCDI was estimated using 1:1 propensity score matching as the difference in hospital stay compared to controls. Controls were hospitalizations without CDI recorded in the Spanish National Hospital Discharge Database. The cost was calculated by multiplying the natural resource units by the unit cost. Costs (euros) were updated to 2019.

Results: We included 282 rCDI episodes (188 as primary diagnosis): 66.31% of patients were aged ≥65 years and 57.80% were female. The mean hospital stay (SD) was 17.18 (23.27) days: 86.17% of rCDI episodes were isolated for a mean (SD) of 10.30 (9.97) days. The total mean cost (95%-CI) per episode was €10,877 (9,499-12,777), of which the hospital stay accounted for 92.56.

Conclusions: There is high cost and resource use associated with rCDI, highlighting the importance of preventing rCDI to the Spanish National Health System.

Citing Articles

Impact of an Intervention Program on Infections: Comparison of 2 Hospital Cohorts.

Kamel S, Corbacho-Loarte M, Escudero-Sanchez R, Halperin A, Llorente S, Quevedo S Open Forum Infect Dis. 2024; 11(7):ofae390.

PMID: 39050227 PMC: 11267231. DOI: 10.1093/ofid/ofae390.


Retrospective Analysis of Infection Rates and Outcomes in Hospitalized Patients during the COVID-19 Pandemic: A Unicenter Study in Reus, Spain.

Iftimie S, Lopez-Azcona A, Corchero-Valverde M, Peralta-Vazquez A, Lopez-Cordon L, Garcia-Cervera C J Clin Med. 2024; 13(10).

PMID: 38792341 PMC: 11122305. DOI: 10.3390/jcm13102799.


Economic Burden of Clostridioides difficile Infection in European Countries.

Reigadas E, Vazquez-Cuesta S, Bouza E Adv Exp Med Biol. 2024; 1435:1-12.

PMID: 38175468 DOI: 10.1007/978-3-031-42108-2_1.


Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Infection.

De la Villa S, Herrero S, Munoz P, Rodriguez C, Valerio M, Reigadas E Open Forum Infect Dis. 2023; 10(2):ofad028.

PMID: 36776780 PMC: 9907541. DOI: 10.1093/ofid/ofad028.


Treatment of Clostridioides difficile infection: from guidelines to clinical practice.

Merino E, Salavert M Rev Esp Quimioter. 2022; 35 Suppl 3:97-101.

PMID: 36285868 PMC: 9717447. DOI: 10.37201/req/s03.21.2022.


References
1.
Esteban-Vasallo M, de Miguel-Diez J, Lopez-de-Andres A, Hernandez-Barrera V, Jimenez-Garcia R . Clostridium difficile-related hospitalizations and risk factors for in-hospital mortality in Spain between 2001 and 2015. J Hosp Infect. 2018; 102(2):148-156. DOI: 10.1016/j.jhin.2018.09.006. View

2.
Soler P, Nogareda F, Cano R . Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005. Infect Control Hosp Epidemiol. 2008; 29(9):887-9. DOI: 10.1086/590392. View

3.
Olsen M, Yan Y, Reske K, Zilberberg M, Dubberke E . Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015; 21(2):164-70. DOI: 10.1016/j.cmi.2014.08.017. View

4.
Debast S, Bauer M, Kuijper E . European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2013; 20 Suppl 2:1-26. DOI: 10.1111/1469-0691.12418. View

5.
Le Monnier A, Duburcq A, Zahar J, Corvec S, Guillard T, Cattoir V . Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect. 2015; 91(2):117-22. DOI: 10.1016/j.jhin.2015.06.017. View